Pneumococcal Disease Clinical Trials

74 clinical trials for Pneumococcal Disease across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants — RECRUITING · PHASE3
• A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. — RECRUITING · PHASE3
• Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines — RECRUITING · PHASE4
• Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS — RECRUITING · PHASE3
• Serum Collection Study for Assay Development — RECRUITING · PHASE1
• Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 — RECRUITING · PHASE4
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V116 IN CHILDREN AND ADOLESCENTS WITH INCREASED RISK OF PNEUMOCOCCAL DISEASE — RECRUITING · PHASE3
• A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People — RECRUITING · PHASE3
• A PHASE 2 MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND, DOSE-RANGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A 25-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY PCV-NAÏVE ADULTS — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V116 IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 TO 64 YEARS OF AGE WITH INCREASED RISK FOR PNEUMOCOCCAL DISEASE — RECRUITING · PHASE3
• A PHASE 3 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY,AND IMMUNOGENICITY OF V116 IN PNEUMOCOCCAL VACCINE-EXPERIENCED ADULTS 50 YEARS OF AGE OR OLDER — RECRUITING · PHASE3
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V114 IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER (PNEU-AGE) — RECRUITING · PHASE3
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF V114 IN HEALTHY INFANTS (PNEU-LINK)/ PROTOCOL 031-00 — RECRUITING · PHASE3
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATORCONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V114 FOLLOWED BY ADMINISTRATION OF PNEUMOVAX TM 23 SIX MONTHS LATER IN IMMUNOCOMPETENT ADULTS BETWEEN 18 AND 49 YEARS OF AGE AT INCREASED RISK FOR PNEUMOCOCCAL DISEASE (PNEU-DAY) — RECRUITING · PHASE3
• A RANDOMIZED CONTROLLED TRIAL TO COMPARE A 1-DOSE VS. 2-DOSE PRIMING SCHEDULE OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CANADIAN INFANTS; A CANADIAN IMMUNIZATION RESEARCH NETWORK (CIRN) STUDY — RECRUITING
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years — OTHER · PHASE3
• Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Administered To Infants In Korea — OTHER · PHASE2
• PCV and EHPC Study — COMPLETED · PHASE4
• A Study to Learn About How a New Pneumococcal Vaccine Works in Infants — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults — COMPLETED · PHASE1
• A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months — ACTIVE_NOT_RECRUITING
• A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Learn About How a New Pneumococcal Vaccine Works in Children — COMPLETED · PHASE2
• Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) — COMPLETED · PHASE3
• A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults — COMPLETED · PHASE1
• Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) — COMPLETED · PHASE3
• Opportunistic Pneumococcal Immunisation Trial in MALnutrition — NOT_YET_RECRUITING · PHASE4
• A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan — COMPLETED · PHASE3
• A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease. — OTHER · PHASE3
• 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan — COMPLETED · PHASE3
• A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India. — COMPLETED · PHASE3
• Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9) — COMPLETED · PHASE3
• A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4) — COMPLETED · PHASE3
• Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) — COMPLETED · PHASE3
• Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 — COMPLETED · PHASE3
• A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults — COMPLETED · PHASE1
• A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India — COMPLETED · PHASE4
• Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age — COMPLETED · PHASE1
• A Phase I Study of XJ103 in Chinese Healthy Subjects — OTHER · PHASE1
• Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age — COMPLETED · PHASE3
• 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants — COMPLETED · PHASE3
• A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine — COMPLETED · PHASE1
• 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants — COMPLETED · PHASE3
• 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants — COMPLETED · PHASE3
• 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants — COMPLETED · PHASE3
• Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 — COMPLETED · PHASE3
• Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age — COMPLETED · PHASE3
• A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator — COMPLETED · PHASE1
• Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults — COMPLETED · PHASE3

Refine this search